AEGIS-II: CSL112 Associated With Lower Rates of CV Death, MIs

Intravenous infusions of CSL112, human plasma-derived apolipoprotein A-I (apoA-I), were associated with numerically lower rates of cardiovascular death and myocardial infarction (MI), according to results from AEGIS-II presented during a Late-Breaking Clinical Trial session at ACC.24 and simultaneously published in the New England Journal of Medicine.

EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute myocardial infarction (MI), according to results of EMPACT-MI, presented during a Late-Breaking Clinical Trial session at ACC.24 and published simultaneously in the New England Journal of Medicine.

BRIDGE-TIMI 73a: Novel Olezarsen Reduces Triglycerides, ApoC3, ApoB Levels

Olezarsen, an investigational drug that blocks production of apolipoprotein C-III (apoC3), may cut triglyceride levels nearly in half, as well as lower apoC3 and apolipoprotein B (apoB) levels in patients with hypertriglyceridemia (HTG) and high cardiovascular risk, according to results of BRIDGE-TIMI 73a presented during a Late-Breaking Clinical Trial session at ACC.24 and published simultaneously in the New England Journal of Medicine.

DEDICATE-DZKH6: Is TAVR Noninferior to SAVR For Low-Risk Patients?

TAVR was found to bring no increased risks and was associated with substantially decreased rates of death or stroke at one year in low-risk patients, vs. surgical aortic valve replacement (SAVR), according to results from DEDICATE-DZHK6 presented during a Late-Breaking Clinical Trial session at ACC.24 and simultaneously published in the New England Journal of Medicine.